Lantheus downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded Lantheus (LNTH) to Neutral from Buy with a price target of $77, down from $110. The firm sees modest risk to consensus sales estimates over the intermediate term and believes a share recovery will be dependent upon Lantheus seeing improving visibility on its organic growth. The stock has significantly underperformed year-to-date due to pricing pressure on Pylarify, slower than anticipated uptake of approved Alzheimer’s disease therapeutics, and some bolt-on acquisitions that have made the drivers of the company’s future growth less predictable, the analyst tells investors in a research note. Goldman views the stock’s risk/reward at balanced at current levels.